Publications by authors named "Reiki Nishimura"

Claim this Profile
D
Delayed Trastuzumab-induced Cardiotoxicity Leading to Severe Left Ventricular Dysfunction.
Ikuo Misumi, Reiki Nishimura, Shota Nakamura, Koji Sato, Miwa Dekita

Intern Med· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel formula to improve the accuracy and prognostic ability of determining the survival time after recurrent breast cancer.
Reiki Nishimura, Yasuaki Sagara, Reiko Mitsueda, Tetsuhiko Taira, Toshiko Miyaki

Breast Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Clinicopathological and Prognostic Significance of HER2-Low Breast Cancer: A Comparative Analysis Between HER2-Low and HER2-Zero Subtypes.
Reiki Nishimura, Yoshitaka Fujiki, Tetsuhiko Taira, Toshiko Miyaki, Shuichi Kanemitsu

Clin Breast Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prospective analysis of two studies that used the 5-mm interval slices and 5-mm margin-free method for ipsilateral breast tumor recurrence after breast-conserving surgery without radiotherapy.
Shozo Ohsumi, Reiki Nishimura, Norikazu Masuda, Sadako Akashi-Tanaka, Kimito Suemasu

Breast Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapy.
Yuichiro Kikawa, Yasuhiro Hagiwara, Tomomi Fujisawa, Kazuhiro Araki, Takayuki Iwamoto, Reiki Nishimura

PLoS One· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An evaluation of lymphovascular invasion in relation to biology and prognosis according to subtypes in invasive breast cancer.
Reiki Nishimura, Tomofumi Osako, Yasuhiro Okumura, Masahiro Nakano, Hiroko Ohtsuka

Oncol Lett· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Triple Negative Breast Cancer: An Analysis of the Subtypes and the Effects of Menopausal Status on Invasive Breast Cancer.
Reiki Nishimura, Tomofumi Osako, Yasuhiro Okumura, Masahiro Nakano, Hiroko Otsuka

J Clin Med· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Correlation Analysis Between Metabolism-related Genes and Treatment Response to S-1 as First-line Chemotherapy for Metastatic Breast Cancer: The SELECT BC-EURECA Study.
Tsutomu Takashima, Fumikata Hara, Takayuki Iwamoto, Yukari Uemura, Shozo Ohsumi, Reiki Nishimura

Clin Breast Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anthracycline-containing regimens or taxane versus S-1 as first-line chemotherapy for metastatic breast cancer.
Hirofumi Mukai, Yukari Uemura, Hiromitsu Akabane, Takanori Watanabe, Youngjin Park, Reiki Nishimura

Br J Cancer· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of neoadjuvant systemic therapy on breast conservation rates in patients with HER2-positive breast cancer: Surgical results from a phase II randomized controlled trial.
Takeshi Yamaguchi, Yasuo Hozumi, Yasuaki Sagara, Masato Takahashi, Kimiyasu Yoneyama, Reiki Nishimura

Surg Oncol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs.
Takayuki Iwamoto, Tomomi Fujisawa, Tadahiko Shien, Kazuhiro Araki, Kentaro Sakamaki, Reiki Nishimura

Breast Cancer· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01.
Hiroyasu Yamashiro, Hiroji Iwata, Norikazu Masuda, Naohito Yamamoto, Reiki Nishimura

Breast Cancer· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study.
Masato Takahashi, Norikazu Masuda, Reiki Nishimura, Kenichi Inoue, Shinji Ohno

Cancer Med· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study.
Hirofumi Mukai, Takeshi Yamaguchi, Masato Takahashi, Yasuo Hozumi, Tomomi Fujisawa, Reiki Nishimura

Br J Cancer· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Microsatellite instability in Japanese female patients with triple-negative breast cancer.
Kanako Kurata, Makoto Kubo, Masaya Kai, Hitomi Mori, Hitomi Kawaji, Reiki Nishimura

Breast Cancer· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study.
Kenji Tamura, Chiyo K Imamura, Toshimi Takano, Shigehira Saji, Takeharu Yamanaka, Reiki Nishimura

J Clin Oncol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T-bet lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancer.
Hitomi Mori, Makoto Kubo, Masaya Kai, Mai Yamada, Kanako Kurata, Reiki Nishimura

Breast Cancer Res Treat· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Participants in a randomized controlled trial had longer overall survival than non-participants: a prospective cohort study.
Shinji Ohno, Hirofumi Mukai, Kazutaka Narui, Yasuo Hozumi, Yasuo Miyoshi, Reiki Nishimura

Breast Cancer Res Treat· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients.
Hirofumi Mukai, Chikako Shimizu, Norikazu Masuda, Shoichiro Ohtani, Shinji Ohno, Reiki Nishimura

Int J Clin Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Ki-67 index value and progesterone receptor status can predict prognosis and suitable treatment in node-negative breast cancer patients with estrogen receptor-positive and HER2-negative tumors.
Nobuyuki Arima, Reiki Nishimura, Tomofumi Osako, Yasuhiro Okumura, Masahiro Nakano

Oncol Lett· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study.
Norikazu Masuda, Reiki Nishimura, Masato Takahashi, Kenichi Inoue, Shinji Ohno

Cancer Sci· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
Reiki Nishimura, Uhi Toh, Maki Tanaka, Michiyo Saimura, Yasuhiro Okumura

Oncology· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer.
Hitomi Mori, Makoto Kubo, Reiki Nishimura, Tomofumi Osako, Nobuyuki Arima

PLoS One· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of eribulin as first- to third-line treatment in patients with advanced or metastatic breast cancer previously treated with anthracyclines and taxanes.
Shigeto Maeda, Michiyo Saimura, Shigeki Minami, Kaname Kurashita, Reiki Nishimura

Breast· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.
Hitomi Mori, Makoto Kubo, Rin Yamaguchi, Reiki Nishimura, Tomofumi Osako

Oncotarget· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis